USPTO issues new patent for Vosaroxin formulation: Sunesis Pharma
Sunesis Pharma said that Vosaroxin is an anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. According
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.